
Dry Age-related Macular Degeneration (Dry-AMD)- Pipeline Insight, 2025
Description
DelveInsight’s, “Dry Age-related Macular Degeneration (Dry-AMD)- Pipeline Insight, 2025” report provides comprehensive insights about 70+ companies and 80+ pipeline drugs in Dry Age-related Macular Degeneration (Dry-AMD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Dry Age-related Macular Degeneration (Dry-AMD): Overview
Age-related macular degeneration (AMD) is a degenerative disease of the center area of the ocular-posterior segment (the macula lutea) that causes slow degeneration in central vision and severe disability in affected persons. “Age-related” means that it mainly occurs with elderly adults, while “Macular” means that the macula part of the eye is damaged. AMD mostly affects people aged above 50, and it was first reported more than 80 years ago. One of the top four causes of blindness in the elderly is AMD. It is also the leading cause of irreversible blindness in the developed countries. A total population of about 170 million individuals is affected with AMD globally, thus being the third leading cause of vision loss in the world. Usually, dry AMD progresses very slowly whereas, some people experience severe visual impairment within days or weeks of the onset of wet AMD. No symptoms appear during the early stage of the disease. During this initial stage, an ophthalmologist can detect drusen long before symptoms occur. Symptoms that typically occur during the intermediate stage include minor alterations in eyesight; however, many people do not have any symptoms at this time. Some people see black or grey areas in the middle of their visual field or have difficulty adapting from a brightly illuminated environment to a dark environment.
Currently, clinicians monitor morphological changes in the retina/RPE/choroid by fundus exam, color fundus photography, FAF, OCT, and infrared (IR) reflectance. In the past two decades, OCT140 imaging technologies have had a profound impact on early detection, monitoring of progression, and treatment-efficacy evaluation of dry AMD. The current generation of commercialized OCT systems, SD-OCT, provides volumetric and cross-sectional views of the retina facilitating the visualization, measurement, monitoring, and phenotyping of the retinal layers and RPE,141–143 hyperreflective foci,144 GA,145,146 and drusen147 in eyes with dry AMD. While SD-OCT imaging is currently widely used in clinics as the standard of care for dry AMD diagnosis and prognosis, some emerging developments in OCT technology may lead to paradigm shifts in the way that dry AMD imaging is performed for research and clinical applications. One such technology is the polarization-sensitive OCT (PS-OCT) with tissue-selective imaging capabilities.
In contrast, there are not any approved treatments for dry AMD. The management of dry AMD consists of observation, regular follow-up evaluations, and documentation for timely recognition of visual function deterioration with appropriate rehabilitation and early CNV detection. Several therapeutic avenues are being investigated, aiming at (1) disease prevention, (2) halting disease progression, and/or (3) restoration of vision. Treatment options includes behavioral and lifestyle modification, age-related eye disease study (AREDS) supplements, reduction of toxic by-products, visual cycle modulators, and anti-inflammatory agents and complement inhibitors, gene therapy and cell based therapies.
""Dry Age-related Macular Degeneration (Dry-AMD)- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dry Age-related Macular Degeneration (Dry-AMD) pipeline landscape is provided which includes the disease overview and Dry Age-related Macular Degeneration (Dry-AMD) treatment guidelines. The assessment part of the report embraces, in depth Dry Age-related Macular Degeneration (Dry-AMD) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dry Age-related Macular Degeneration (Dry-AMD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Dry Age-related Macular Degeneration (Dry-AMD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dry Age-related Macular Degeneration (Dry-AMD) Emerging Drugs
Further product details are provided in the report……..
Dry Age-related Macular Degeneration (Dry-AMD): Therapeutic Assessment
This segment of the report provides insights about the different Dry Age-related Macular Degeneration (Dry-AMD) drugs segregated based on following parameters that define the scope of the report, such as:
Dry Age-related Macular Degeneration (Dry-AMD): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dry Age-related Macular Degeneration (Dry-AMD) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dry Age-related Macular Degeneration (Dry-AMD) drugs.
Dry Age-related Macular Degeneration (Dry-AMD) Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Dry Age-related Macular Degeneration (Dry-AMD): Overview
Age-related macular degeneration (AMD) is a degenerative disease of the center area of the ocular-posterior segment (the macula lutea) that causes slow degeneration in central vision and severe disability in affected persons. “Age-related” means that it mainly occurs with elderly adults, while “Macular” means that the macula part of the eye is damaged. AMD mostly affects people aged above 50, and it was first reported more than 80 years ago. One of the top four causes of blindness in the elderly is AMD. It is also the leading cause of irreversible blindness in the developed countries. A total population of about 170 million individuals is affected with AMD globally, thus being the third leading cause of vision loss in the world. Usually, dry AMD progresses very slowly whereas, some people experience severe visual impairment within days or weeks of the onset of wet AMD. No symptoms appear during the early stage of the disease. During this initial stage, an ophthalmologist can detect drusen long before symptoms occur. Symptoms that typically occur during the intermediate stage include minor alterations in eyesight; however, many people do not have any symptoms at this time. Some people see black or grey areas in the middle of their visual field or have difficulty adapting from a brightly illuminated environment to a dark environment.
Currently, clinicians monitor morphological changes in the retina/RPE/choroid by fundus exam, color fundus photography, FAF, OCT, and infrared (IR) reflectance. In the past two decades, OCT140 imaging technologies have had a profound impact on early detection, monitoring of progression, and treatment-efficacy evaluation of dry AMD. The current generation of commercialized OCT systems, SD-OCT, provides volumetric and cross-sectional views of the retina facilitating the visualization, measurement, monitoring, and phenotyping of the retinal layers and RPE,141–143 hyperreflective foci,144 GA,145,146 and drusen147 in eyes with dry AMD. While SD-OCT imaging is currently widely used in clinics as the standard of care for dry AMD diagnosis and prognosis, some emerging developments in OCT technology may lead to paradigm shifts in the way that dry AMD imaging is performed for research and clinical applications. One such technology is the polarization-sensitive OCT (PS-OCT) with tissue-selective imaging capabilities.
In contrast, there are not any approved treatments for dry AMD. The management of dry AMD consists of observation, regular follow-up evaluations, and documentation for timely recognition of visual function deterioration with appropriate rehabilitation and early CNV detection. Several therapeutic avenues are being investigated, aiming at (1) disease prevention, (2) halting disease progression, and/or (3) restoration of vision. Treatment options includes behavioral and lifestyle modification, age-related eye disease study (AREDS) supplements, reduction of toxic by-products, visual cycle modulators, and anti-inflammatory agents and complement inhibitors, gene therapy and cell based therapies.
""Dry Age-related Macular Degeneration (Dry-AMD)- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dry Age-related Macular Degeneration (Dry-AMD) pipeline landscape is provided which includes the disease overview and Dry Age-related Macular Degeneration (Dry-AMD) treatment guidelines. The assessment part of the report embraces, in depth Dry Age-related Macular Degeneration (Dry-AMD) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dry Age-related Macular Degeneration (Dry-AMD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Dry Age-related Macular Degeneration (Dry-AMD) R&D. The therapies under development are focused on novel approaches to treat/improve Dry Age-related Macular Degeneration (Dry-AMD).
This segment of the Dry Age-related Macular Degeneration (Dry-AMD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dry Age-related Macular Degeneration (Dry-AMD) Emerging Drugs
- Tinlarebant (LBS-008): Belite Bio
- XIFLAM: Inflammx Therapeutics
- OCU410: Ocugen
- OLX301A: OliX Pharmaceuticals
- GS030: Gensight Biologics
Further product details are provided in the report……..
Dry Age-related Macular Degeneration (Dry-AMD): Therapeutic Assessment
This segment of the report provides insights about the different Dry Age-related Macular Degeneration (Dry-AMD) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Dry Age-related Macular Degeneration (Dry-AMD)
- There are approx. 70+ key companies which are developing the therapies for Dry Age-related Macular Degeneration (Dry-AMD). The companies which have their Dry Age-related Macular Degeneration (Dry-AMD) drug candidates in the most advanced stage, i.e. Phase III include, Belite Bio
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Dry Age-related Macular Degeneration (Dry-AMD): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dry Age-related Macular Degeneration (Dry-AMD) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dry Age-related Macular Degeneration (Dry-AMD) drugs.
Dry Age-related Macular Degeneration (Dry-AMD) Report Insights
- Dry Age-related Macular Degeneration (Dry-AMD) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Dry Age-related Macular Degeneration (Dry-AMD) drugs?
- How many Dry Age-related Macular Degeneration (Dry-AMD) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dry Age-related Macular Degeneration (Dry-AMD)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dry Age-related Macular Degeneration (Dry-AMD) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Dry Age-related Macular Degeneration (Dry-AMD) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Belite Bio
- Inflammx Therapeutics
- Ocugen
- OliX Pharmaceuticals
- Gensight Biologics
- Alkeus Pharmaceuticals
- Dobecure
- Cognition Therapeutics
- Aviceda Therapeutics
- Galimedix Therapeutics
- Mitotech
- Annexon, Inc.
- NGM Biopharmaceuticals
- Johnson & Johnson
- Lineage Cell Therapeutics
- Astellas Pharma
- Regenerative Patch Technologies
- Hoffmann-La Roche
- Boehringer Ingelheim
- ONL Therapeutics
- Tinlarebant (LBS-008)
- XIFLAM
- OCU410
- OLX301A
- GS030
- ALK-001
- Etamsylate
- CT1812
- AVD-104
- GAL-101(Topical)
- Visomitin
- ANX 007
- NGM621
- JNJ 81201887
- OpRegen
- MA09-hRPE
- CPCB-RPE1
- RO7303359
- BI 771716
- ONL1204
Table of Contents
240 Pages
- Introduction
- Executive Summary
- Dry Age-related Macular Degeneration (Dry-AMD): Overview
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Dry Age-related Macular Degeneration (Dry-AMD)– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Tinlarebant (LBS-008): Belite Bio
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- XIFLAM: Inflammx Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- OCU410: Ocugen
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- GS030: Gensight Biologics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Dry Age-related Macular Degeneration (Dry-AMD) Key Companies
- Dry Age-related Macular Degeneration (Dry-AMD) Key Products
- Dry Age-related Macular Degeneration (Dry-AMD)- Unmet Needs
- Dry Age-related Macular Degeneration (Dry-AMD)- Market Drivers and Barriers
- Dry Age-related Macular Degeneration (Dry-AMD)- Future Perspectives and Conclusion
- Dry Age-related Macular Degeneration (Dry-AMD) Analyst Views
- Dry Age-related Macular Degeneration (Dry-AMD) Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.